Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study

Authors
Publication date
1 January 2018
Publisher
Digital Commons@Becker

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Digital Commons@Becker

    redirect
    oaioai:digitalcommons.wustl.edu:o...
    Last time updated on 06/11/2019